NanoLogix Announces Commercial Collaboration With Advanced Medical German Company of Kuwait

Kuwaiti company to control Middle East, North and East Africa for marketing, sales and production of NanoLogix technologies

HUBBARD, OH DECEMBER 20, 2010-NanoLogix (OTC MARKETS: NNLX), an innovator in the accelerated detection and identification of microorganisms, is pleased to announce its collaboration with Advanced Medical German Company of Kuwait (AMGKWT). This alliance will support NanoLogix’s market penetration goals for the Middle East, North and East Africa with the international marketing focus of Advanced Medical German Company stretching from the Middle East through Africa.

“This collaboration with NanoLogix reinforces our commitment to providing exceptional and innovative health care solutions,?said Dr. Eyad Al Saleh, MD, President and CEO of Advanced Medical German Company. “We are pleased to work with NanoLogix, whose technologies enhance our mission to meet growing laboratory demand for faster test results and reduced testing costs.?/p>

“We are confident this association with Advanced Medical German Company marks a new chapter in our company evolution,?said NanoLogix CEO Bret Barnhizer. “This endeavor complements our ongoing work with the University of Texas Health Science Center - Houston, The US EPA and others. It supports our goal of international market entry and provides access for our technology to important life science markets in the Middle East and Africa, with a regional population of over 700 million. In addition to marketing, sales and production operations through AMGKWT, we look forward to their assistance as required with certification and validation of our rapid detection and identification technologies.?

Contact between NanoLogix and Advanced Medical German Company was initiated in 2009 and advanced in 2010 with a visit to Kuwait and Dubai by NanoLogix CEO Bret Barnhizer and Director John Chatterton.

CEO Barnhizer plans to attend Arab Health 2011, the world's second-largest medical exhibition, in Dubai January 24 - 27, where AMGKWT will be an exhibitor. For information on Arab Health 2011:

About Advanced Medical German Company

The Advanced Medical German Company provides complete, cost-effective, quality assured health care services through pioneering life science, medical, pharmaceutical departments and laboratories. The company deals with products and services for early detection, prevention, and diagnosis, as well as drugs for the treatment of diseases. AMGKWT provides products and services tailored to the needs of a wide range of organizations, doctors and patient groups. Information on Advanced Medical German Company is available at:

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit

More information on NanoLogix is available at:

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Media Contact:
Lisa Ann Pinkerton

Investor Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800

Copyright 2011 NanoLogix, Inc All Rights Reserved